Macular Degeneration: Stop the Vision Loss Epidemic
On Saturday, February 18th, 2012, the Macular Degeneration Association (MDA) will host an educational symposium in Glendale, Arizona at the Renaissance Hotel & Spa, located at 9495 W. Coyotes Blvd. The event is designed to give an overview of age-related macular degeneration (AMD), including the progression of the disease and the dangers of vision loss as a result.
- Phoenix-Mesa, AZ (1888PressRelease) February 01, 2012 - MACULAR DEGENERATION ASSOCIATION
ANNOUNCES
STOP THE VISION LOSS EPIDEMIC!
EDUCATIONAL SYMPOSIUM
SATURDAY, February 18th, 2012 8:30 a.m. - 2:30 p.m.
RENAISSANCE HOTEL & SPA
9495 W. COYOTES BLVD, GLENDALE, AZ 85305
On Saturday, February 18th, 2012, the Macular Degeneration Association (MDA) will host an educational symposium in Glendale, Arizona at the Renaissance Hotel & Spa, located at 9495 W. Coyotes Blvd. The event is designed to give an overview of age-related macular degeneration (AMD), including the progression of the disease and the dangers of vision loss as a result. The symposium will also cover precautionary methods, nutritional benefits and low vision rehabilitation that may delay the onset of AMD and reduce retinal damage.
Event attendees will learn the latest treatment advances evolving in the macular field, including the revolutionary Macula RiskŪ test, a new genetic test predicting one's likelihood of developing AMD. In addition to establishing an individual's genetic predisposition to macular degeneration, the test is also useful in formulating a customized treatment plan for those already diagnosed with AMD.
Exhibitors, featured event speakers, and distinguished guests will offer participants many opportunities to learn about the latest advances in macular degeneration research, precautionary methods, medications, treatments and low vision therapies. AMD treatment pioneer Dr. Michael Tolentino, renowned for developing revolutionary treatment strategies to slow the progression of macular degeneration, will explain the dangers of vision loss and the importance of genetic testing for both the general population at large and those already diagnosed with macular degeneration.
MDA's educational symposium in Glendale will provide attendees with a unique opportunity to interact with nationally known macular experts, local doctors, fellow patients and caregivers in an open forum.
To register for the upcoming symposium in Glendale, please call (941) 870-4399 or via email info ( @ ) maculardegenerationassociation dot org dot
About the Macular Degeneration Association (MDA)
The Macular Degeneration Association is a nonprofit health organization dedicated to educating and empowering age-related macular degeneration patients all across the world. Age-related macular degeneration (AMD) is an increasingly prevalent degenerative eye disease, affecting millions of aging seniors. The mission of MDA is to educate patients on the latest advances in treating AMD. However, our focus extends far beyond diagnosed patients. We are committed to the senior population at large, those most at risk of developing macular degeneration.
Our goal is to provide information about risk factors, genetic predisposition, and proper diagnosis, as well as preventative efforts and treatment options that will likely reduce the most adverse effect of AMD, blindness. MDA is passionate about funding and developing sophisticated patient education and advocacy programs designed to improve macular patients' quality of life. This is accomplished through the Association's patient education conferences and seminars held nationwide.
The Association honors its commitment to prioritizing patient education by aligning itself with experts in the macular field, investigating retina-related scientific breakthroughs, and disseminating new scientific advances to macular patients across the world. We strongly believe that providing support, education and empowerment to the millions of people living with age-related macular degeneration will improve patient quality of life, and energize the retina field to develop advances in treating AMD.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam